Stockreport

BeiGene Announces Acceptance of a Supplemental New Drug Application for Tislelizumab in Combination with Chemotherapy in First-Line Advanced Squamous Non-Small Cell Lung Cancer in China

BeiGene, Ltd. - American Depositary Shares  (BGNE) 
Last beigene, ltd. - american depositary shares earnings: 3/2 04:05 pm Check Earnings Report
PDF BEIJING, China and CAMBRIDGE, Mass., April 20, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on [Read more]